Molecular Medicine : Financial calendar for fiscal year 2017

PRESS RELEASE

Financial calendar for fiscal year 2017

Milan (Italy), January 30, 2017 - Please find here below the financial calendar of MolMed S.p.A. (MLM.MI) for fiscal year 2017. The calendar is available on MolMed's website (www.molmed.com). Any amendments will be promptly communicated to the market.

Board of Directors

DATE	SUBJECT
6 MARCH 2017	Approval of draft statutory financial statements for FY 2016
8 MAY 2017	Approval of interim financial report at 31/03/2017(*)
27 JULY 2017	Approval of half-year financial report at 30/06/2017
6 NOVEMBER 2017	Approval of interim financial report at 30/09/2017(*)

(*) additional interim financial information

Shareholders' Meeting

DATE	SUBJECT
10 APRIL 2017	Approval of statutory financial statements for FY 2016

Under the new regulations in force1 and in order to ensure continuity with the past, MolMed decided to continue the publication of quarterly reports as additional interim financial information ("Additional Info"), on a voluntary basis and until otherwise decided, as already done during fiscal year 2016, with the same form and content to those of the previous fiscal years.

The Additional Info will be subject to approval by the Board of Directors (the "Board") in meetings to be held within 45 days from the end of the first and third quarter of each fiscal year, and will be disclosed to the market, again within 45 days from the end of the first and third quarter of each fiscal year, by means of:

• issuance of a press release upon the conclusion of the Board meeting approving the interim financial information;

• publication of the Additional Info on the corporate website (www.molmed.com) within the section devoted to financial reports.

This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.

1 Italian Legislative Decree n. 25/2016 implementing Directive 2013/50/EU (the "Decree") eliminated the mandatory requirement to publish the quarterly interim financial reports, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998 (the "TUF"). The Decree also granted to Consob the powers of providing for any additional disclosure requirements beyond the annual and half- year financial statements. On the basis of the powers granted by the Decree, Consob - by way of resolution

n. 19770 of October 26, 2016 - introduced some amendments to the Issuers' Regulation concerning additional interim financial information (new Article 82-ter), in force from January 2, 2017.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone [phone] - Fax [phone] [e-mail] - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

COMUNICATO STAMPA

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR- CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and has an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

phone: [phone]

fax: [phone]

e-mail: [e-mail]

Andrea Quaglino

Administration, Finance & Control Director

MolMed S.p.A.

phone: [phone]

fax: [phone]

e-mail: [e-mail]

FROM GENES TO THERAPY

2